Scarica l'app Stockscreener
3.955
0.00%
0.005
Precedente Chiudi:
$3.96
Aprire:
$3.95
Volume 24 ore:
718.14K
Relative Volume:
0.40
Capitalizzazione di mercato:
$255.66M
Reddito:
-
Utile/perdita netta:
$-71.17M
Rapporto P/E:
-2.8453
EPS:
-1.39
Flusso di cassa netto:
$-70.97M
1 W Prestazione:
+0.25%
1M Prestazione:
+303.83%
6M Prestazione:
+40.93%
1 anno Prestazione:
-13.16%
Intervallo 1D:
$3.95
$3.96
Intervallo di 1 settimana:
$3.94
$3.99
Portata 52W:
$0.721
$6.24
Inozyme Pharma Inc Stock (INZY) Company Profile
Nome
Inozyme Pharma Inc
Settore
Industria
Telefono
857-330-4340
Indirizzo
321 SUMMER STREET, BOSTON
Confronta INZY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
3.96 | 91.68M | 0 | -71.17M | -70.97M | -1.39 |
|
ONC
Beigene Ltd Adr
|
241.99 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.94 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.31 | 42.47M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
590.83 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Raymond James | Outperform |
| 2024-09-12 | Iniziato | Stifel | Buy |
| 2024-08-13 | Ripresa | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2023-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-26 | Iniziato | Jefferies | Hold |
| 2022-02-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-29 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Wedbush | Outperform |
Mostra tutto
Inozyme Pharma Inc Borsa (INZY) Ultime notizie
Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - Zacks Investment Research
BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN
BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire
BioMarin agrees to acquire Inozyme for $270m - MSN
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN
BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSETXNM), Servotronics, Inc. (NYSE AmericanSVT), Protagenic Therapeutics, Inc. (Nasdaq – - TradingView
BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha
Piper Sandler Downgrades Inozyme Pharma to Neutral From Overweight, Lowers Price Target to $4 From $23 - marketscreener.com
TD Cowen Downgrades Inozyme Pharma to Hold From Buy, Price Target is $4 - marketscreener.com
Raymond James Downgrades Inozyme Pharma to Market Perform From Outperform - marketscreener.com
BioMarin to acquire Inozyme to enhance its enzyme therapy portfolio - World Pharmaceutical Frontiers
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders - GlobeNewswire Inc.
BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0
StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News
The week in pharma: action, reaction and insight – week to May 16 - The Pharma Letter
Wells Fargo & Company Reaffirms Equal Weight Rating for Inozyme Pharma (NASDAQ:INZY) - Defense World
Inozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Wedbush - Defense World
Inozyme Pharma (NASDAQ:INZY) Earns Hold Rating from Jefferies Financial Group - Defense World
BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN
Leerink bullish on BioMarin following Inozyme deal, expects additional BD - Yahoo Finance
Wedbush Has Negative Outlook for Inozyme Pharma Q2 Earnings - Defense World
Inozyme Pharma (INZY) Downgraded by Needham Analyst | INZY Stock News - GuruFocus
Inozyme downgraded to Hold from Buy at TD Cowen - TipRanks
BioMarin to acquire Inozyme for $270 million By Investing.com - Investing.com South Africa
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock New - GuruFocus
BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business - insights.citeline.com
Inozyme Pharma (INZY) Downgraded by Wells Fargo | INZY Stock News - GuruFocus
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 - Investing.com Nigeria
Inozyme stock rating cut to Hold at Jefferies, target to $4 from $15 By Investing.com - Investing.com South Africa
Inozyme (INZY) Downgraded Following Acquisition Deal | INZY Stoc - GuruFocus
TD Cowen cuts Inozyme stock rating post-acquisition news - Investing.com Australia
TD Cowen cuts Inozyme stock rating post-acquisition news By Investing.com - Investing.com Nigeria
Biomarin snags potential ‘first-in-disease’ ERT in $270M Inozyme buy - BioWorld MedTech
BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease - MedCity News
Inozyme Pharma (INZY) Sees Price Target Slash and Downgrade by J - GuruFocus
Inozyme Pharma’s Strategic Acquisition by Biomarin: Analyst Holds Rating Amid Favorable Shareholder Outcome and Strategic Alignment - TipRanks
Inozyme (INZY) Downgraded Following Acquisition by BioMarin | INZY Stock News - GuruFocus
Dollar Stock Skyrockets 179% On BioMarin Takeover - Investor's Business Daily
BioMarin stock rises following Inozyme Pharma acquisition By Investing.com - Investing.com Nigeria
BioMarin stock rises following Inozyme Pharma acquisition - Investing.com Australia
BioMarin to acquire Inozyme for $4.00 per share in cash, or $270M - TipRanks
Jefferies Downgrades Inozyme Pharma to Neutral From Buy - marketscreener.com
BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges - TipRanks
Jefferies Downgrades Inozyme (INZY) After Acquisition Announceme - GuruFocus
Jefferies Downgrades Inozyme (INZY) After Acquisition Announcement | INZY Stock News - GuruFocus
Inozyme downgraded to Hold from Buy at Jefferies - TipRanks
Inozyme Pharma Inc Azioni (INZY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Inozyme Pharma Inc Azioni (INZY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Treco Douglas A | CEO & Chairman |
Apr 02 '25 |
Sale |
0.89 |
8,819 |
7,849 |
41,046 |
17.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):